Scholarlink

<p>Fluoropyrimidines, including 5-fluorouracil (5-FU), used in the treatment of patients with gastrointestinal malignancies, are associated with cardiotoxicity. Although the mechanism of this cardiotoxicity remains unknown, rat models treated with 5-FU have higher iron concentrations in myocardial tissue compared to controls. As a result, we sought to examine whether ferritin could be a clinical biomarker of cardiotoxicity among patients receiving 5-FU-based chemotherapy. We conducted a retrospective chart review on adult patients receiving 5-FU-based intravenous chemotherapy at a single academic center from June 2022 to 2024. Potential cardiotoxicity was defined by obstructive coronary artery disease, new wall motion abnormalities on transthoracic echocardiography (TTE), left ventricular ejection fraction decrease ≥10% from pre-treatment TTE, coronary vasospasm, pericardial effusion, or incident heart failure. Of our 93 patients, those with ferritin ≥ 100 ng/mL were nearly 5 times as likely to exhibit potential cardiotoxicity (adjusted odds ratio [aOR] 4.7, confidence interval [CI] 1.0-23.5) (Fig. <InternalRef RefID="Fig1">1</InternalRef>A). Similarly, patients with ferritin ≥ 100 ng/mL were approximately 3 times as likely to experience treatment failure (aOR 3.2, CI 1.1–9.7). Based on the apparent relationship between ferritin ≥100 ng/mL, cardiotoxicity, and treatment outcomes, we encourage oncologists to routinely obtain iron studies in addition to pre- and post-treatment TTE among patients receiving 5-FU.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Finding ferritin footprints in 5-fluorouracil-induced cardiotoxicity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月10日

查看全文
  • Grace M. Ferri,
  • Manuel Urina-Jassir,
  • Alexander V. Stanisic,
  • Jack M. Hensien,
  • Grace Lee,
  • Neal Sullivan,
  • Omar K. Siddiqi

摘要

Fluoropyrimidines, including 5-fluorouracil (5-FU), used in the treatment of patients with gastrointestinal malignancies, are associated with cardiotoxicity. Although the mechanism of this cardiotoxicity remains unknown, rat models treated with 5-FU have higher iron concentrations in myocardial tissue compared to controls. As a result, we sought to examine whether ferritin could be a clinical biomarker of cardiotoxicity among patients receiving 5-FU-based chemotherapy. We conducted a retrospective chart review on adult patients receiving 5-FU-based intravenous chemotherapy at a single academic center from June 2022 to 2024. Potential cardiotoxicity was defined by obstructive coronary artery disease, new wall motion abnormalities on transthoracic echocardiography (TTE), left ventricular ejection fraction decrease ≥10% from pre-treatment TTE, coronary vasospasm, pericardial effusion, or incident heart failure. Of our 93 patients, those with ferritin ≥ 100 ng/mL were nearly 5 times as likely to exhibit potential cardiotoxicity (adjusted odds ratio [aOR] 4.7, confidence interval [CI] 1.0-23.5) (Fig. 1A). Similarly, patients with ferritin ≥ 100 ng/mL were approximately 3 times as likely to experience treatment failure (aOR 3.2, CI 1.1–9.7). Based on the apparent relationship between ferritin ≥100 ng/mL, cardiotoxicity, and treatment outcomes, we encourage oncologists to routinely obtain iron studies in addition to pre- and post-treatment TTE among patients receiving 5-FU.